TY - JOUR AU - Turajlic, S. AU - Swanton, C. PY - 2016 DA - 2016// TI - Metastasis as an evolutionary process JO - Science VL - 352 UR - https://doi.org/10.1126/science.aaf2784 DO - 10.1126/science.aaf2784 ID - Turajlic2016 ER - TY - JOUR AU - Heinzerling, L. AU - Baiter, M. AU - Kuhnapfel, S. PY - 2013 DA - 2013// TI - Mutation landscape in melanoma patients, clinical implications of heterogeneity of BRAF mutations JO - Br J Cancer VL - 109 UR - https://doi.org/10.1038/bjc.2013.622 DO - 10.1038/bjc.2013.622 ID - Heinzerling2013 ER - TY - JOUR AU - Helias-Rodzewicz, Z. AU - Funck-Brentano, E. AU - Baudoux, L. PY - 2015 DA - 2015// TI - Variations in BRAF mutant allele percentage in melanomas JO - BMC Cancer VL - 15 UR - https://doi.org/10.1186/s12885-015-1515-3 DO - 10.1186/s12885-015-1515-3 ID - Helias-Rodzewicz2015 ER - TY - JOUR AU - Helias-Rodzewicz, Z. AU - Funck-Brentano, E. AU - Terrones, N. PY - 2017 DA - 2017// TI - Variation of mutant allele frequency in NRASQ61 mutated melanomas JO - BMC Dermatol VL - 17 UR - https://doi.org/10.1186/s12895-017-0061-x DO - 10.1186/s12895-017-0061-x ID - Helias-Rodzewicz2017 ER - TY - JOUR AU - Cheng, L. AU - Lopez-Beltran, A. AU - Massari, F. PY - 2018 DA - 2018// TI - Molecular resting for BRAF mutations to inform melanoma treatment decisions: a move toward peecision medicine JO - Modern Pathol VL - 31 UR - https://doi.org/10.1038/modpathol.2017.104 DO - 10.1038/modpathol.2017.104 ID - Cheng2018 ER - TY - JOUR AU - Boursault, L. AU - Haddad, V. AU - Vergier, B. PY - 2013 DA - 2013// TI - Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0070826 DO - 10.1371/journal.pone.0070826 ID - Boursault2013 ER - TY - JOUR AU - Colombino, M. AU - Capone, M. AU - Lissia, A. PY - 2012 DA - 2012// TI - BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.41.2452 DO - 10.1200/JCO.2011.41.2452 ID - Colombino2012 ER - TY - JOUR AU - Yancovitz, M. AU - Litterman, A. AU - Yoon, J. PY - 2012 DA - 2012// TI - Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0029336 DO - 10.1371/journal.pone.0029336 ID - Yancovitz2012 ER - TY - JOUR AU - Bradish, J. R. AU - Richey, J. D. AU - Post, K. M. PY - 2015 DA - 2015// TI - Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy JO - Mod Pathol VL - 28 UR - https://doi.org/10.1038/modpathol.2014.136 DO - 10.1038/modpathol.2014.136 ID - Bradish2015 ER - TY - JOUR AU - Kaji, T. AU - Yamasaki, O. AU - Takata, M. PY - 2017 DA - 2017// TI - Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: a clue for intra- and inter-tumor heterogeneity JO - J Dermatol Sci VL - 85 UR - https://doi.org/10.1016/j.jdermsci.2016.10.006 DO - 10.1016/j.jdermsci.2016.10.006 ID - Kaji2017 ER - TY - JOUR AU - Bruno, W. AU - Martinuzzi, C. AU - Andreotti, V. PY - 2017 DA - 2017// TI - Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry JO - Oncotarget VL - 8 ID - Bruno2017 ER - TY - JOUR AU - Ding, L. i. AU - Kim, M. i. n. j. u. n. g. AU - Kanchi, K. r. i. s. h. n. a. L. AU - Dees, N. a. t. h. a. n. D. AU - Lu, C. h. a. r. l. e. s. AU - Griffith, M. a. l. a. c. h. i. AU - Fenstermacher, D. a. v. i. d. AU - Sung, H. y. e. r. a. n. AU - Miller, C. h. r. i. s. t. o. p. h. e. r. A. AU - Goetz, B. r. i. a. n. AU - Wendl, M. i. c. h. a. e. l. C. AU - Griffith, O. b. i. AU - Cornelius, L. y. n. n. A. AU - Linette, G. e. r. a. l. d. P. AU - McMichael, J. o. s. h. u. a. F. AU - Sondak, V. e. r. n. o. n. K. AU - Fields, R. y. a. n. C. AU - Ley, T. i. m. o. t. h. y. J. AU - Mulé, J. a. m. e. s. J. AU - Wilson, R. i. c. h. a. r. d. K. AU - Weber, J. e. f. f. r. e. y. S. PY - 2014 DA - 2014// TI - Clonal Architectures and Driver Mutations in Metastatic Melanomas JO - PLoS ONE VL - 9 UR - https://doi.org/10.1371/journal.pone.0111153 DO - 10.1371/journal.pone.0111153 ID - Ding2014 ER - TY - JOUR AU - Sanborn, J. Z. AU - Chung, J. AU - Purdom, E. PY - 2015 DA - 2015// TI - Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination JO - PNAS VL - 112 UR - https://doi.org/10.1073/pnas.1508074112 DO - 10.1073/pnas.1508074112 ID - Sanborn2015 ER - TY - JOUR AU - Satzger, I. AU - Marks, L. AU - Merick, M. AU - Klages, S. PY - 2015 DA - 2015// TI - Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.5634 DO - 10.18632/oncotarget.5634 ID - Satzger2015 ER - TY - JOUR AU - Lebbé, C. AU - How-Kit, A. AU - Battistella, M. PY - 2014 DA - 2014// TI - BRAFV600 mutation levels predict response to vemurafenib in metastatic melanoma JO - Melanoma Res VL - 24 UR - https://doi.org/10.1097/CMR.0000000000000088 DO - 10.1097/CMR.0000000000000088 ID - Lebbé2014 ER - TY - JOUR AU - Mesbah Ardakani, N. AU - Leslie, C. AU - Grieu-Iacopetta, F. PY - 2017 DA - 2017// TI - Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma JO - Pigment Cell Mel Res VL - 30 UR - https://doi.org/10.1111/pcmr.12569 DO - 10.1111/pcmr.12569 ID - Mesbah Ardakani2017 ER - TY - JOUR AU - Boespflug, A. AU - Funck-Brentano, E. AU - Helias-Rodzewicz, Z. PY - 2017 DA - 2017// TI - Reply to clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma by Mesbah Ardakani JO - Pigment Cell Mel Res VL - 30 UR - https://doi.org/10.1111/pcmr.12606 DO - 10.1111/pcmr.12606 ID - Boespflug2017 ER - TY - JOUR AU - Dienstmann, R. AU - Elez, E. AU - Argiles, G. AU - Matos, I. PY - 2017 DA - 2017// TI - Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights JO - Mol Oncol VL - 11 UR - https://doi.org/10.1002/1878-0261.12099 DO - 10.1002/1878-0261.12099 ID - Dienstmann2017 ER - TY - JOUR AU - Chang, G. A. AU - Polsky, D. PY - 2015 DA - 2015// TI - Mutational heterogeneity in melanoma: an inconvenient truth JO - J Invest Dermatol VL - 135 UR - https://doi.org/10.1038/jid.2015.351 DO - 10.1038/jid.2015.351 ID - Chang2015 ER - TY - JOUR AU - Adler, N. R. AU - Wolfe, R. AU - Kelly, J. W. PY - 2017 DA - 2017// TI - Tumour mutation status and sites of metastasis in patients with cutaneous melanoma JO - Br J Cancer VL - 117 UR - https://doi.org/10.1038/bjc.2017.254 DO - 10.1038/bjc.2017.254 ID - Adler2017 ER - TY - JOUR AU - Alizadeh, A. A. AU - Aranda, V. AU - Bardelli, A. PY - 2017 DA - 2017// TI - Toward understanding and exploiting tumor heterogeneity JO - Nature Med VL - 21 UR - https://doi.org/10.1038/nm.3915 DO - 10.1038/nm.3915 ID - Alizadeh2017 ER - TY - JOUR AU - Macintyre, G. AU - Loo, P. AU - Corcoran, N. M. PY - 2017 DA - 2017// TI - How subclonal modeling is changing the metastatic paradigm JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-0234 DO - 10.1158/1078-0432.CCR-16-0234 ID - Macintyre2017 ER - TY - JOUR AU - Menzies, A. M. AU - Long, G. V. PY - 2014 DA - 2014// TI - Dabrafenib and Trametinib, alone and in combination for BRAF-mutant metastatic melanoma JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2054 DO - 10.1158/1078-0432.CCR-13-2054 ID - Menzies2014 ER - TY - JOUR AU - Medina, T. M. AU - Lewis, K. D. PY - 2016 DA - 2016// TI - The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib JO - Onco Targets Ther VL - 9 ID - Medina2016 ER -